New York, Sept. 12, 2022 (GLOBE NEWSWIRE) — Kenneth Research has published an in-depth market report on “Global Immunoassays in the R&D market‘ for the forecast period, i.e. 2022 – 2031, which includes the following factors:
- Market growth over the forecast period
- Detailed regional summary
- market segmentation
- Growth drivers and challenges
- Profiling of key market players
Global Immunoassays R&D Market Size:
It is estimated that the global Immunoassay R&D Market market will achieve remarkable revenue by growing at approx. 18% CAGR during the forecast period i.e. 2022 – 2031. The growth of the market is attributed to the increase in cancer, autoimmune diseases, infectious diseases, endocrine disorders and other chronic diseases for which immunoassays are used in research and development. According to the World Health Organization (WHO), cancer is the leading cause of death and in 2020 there were about 10 million deaths or almost one death from sexual intercourse. An increase in cancer rate has led to higher cancer research spending and is expected to boost the growth of the global immunoassay R&D market. In addition, environmental issues and increasing pollution increase the risk of autoimmune diseases that require better drugs to fight the diseases. Therefore, increasing environmental issues are also expected to be a factor driving the market growth. Additionally, the growth of the market is attributed to the increasing prevalence of cancer, awareness of cancer patients for early disease detection, increasing global per capita healthcare expenditure, and advances in biotechnology and pharmacy.
Get a sample PDF of this report @ https://www.kennethresearch.com/sample-request-10094814
Global Immunoassays in the R&D Market: Key Takeaways
- The Asia-Pacific region accounts for the majority of sales
- The cancer research segment dominates the sales chart
- The Software & Services segment remains prominent in the Products & Services segment
Increasingly…
